| Epilepsy (101) |  |
| Epileptic seizure (21) | |
| Epilepsy (101) | |
| Epileptic seizure (21) | |
and provides a new way to study both the normal brain and brain disorders such as epilepsy and autism.
epilepsy or intellectual disability (see this review article for further background). But they also can be completely benign
#Promising future for tiny epilepsy defibrillator Antal Berényi combined a boyhood passion for electronics and years of medical training to build a device that,
and stop epileptic attacks just as a defibrillator corrects heart arrhythmia. Like its inventor, the prototype device,
and stop epileptic attacks without drugs and without major brain surgery. To the 50 million people worldwide who suffer from epileptic seizures a chronic neurobiological disorder this simple plan could transform their lives.
Working with the renowned scientist Dr György Buzsáki of CMBN Rutgers, State university of New jersey (US), he not only built the prototype device,
when an epileptic seizure is coming and applies tiny, on-demand electric pulses which help the brain return to normal functioning.
especially for the 30%of epileptics who cannot be treated with drugs. The fact that the device can be implanted in a minimally invasive way is"crucial"
and the project's work has gained wider attention following the November publication in Science magazine of the team's findings on'Closed-loop control of epilepsy by trans-cranial electrical stimulation'.
Neurosurgeon Francesco Cardinale is a specialist in epilepsy surgery. He helped the robot engineers at Politecnico di Milano understand what doctors really need.
rug-resistant epilepsy, Parkinsons and other motor skill problems like for example dystonia, chronic pain and all types of brain cancer, said Cardinale.
#Brain surgery robot would go through the cheek Vanderbilt University Posted by David Salisbury-VU on October 16 2014for people with severe epilepsy treatment can mean drilling through the skull deep into the brain
if it was possible to address epileptic seizures in a less invasive way? They decided it would be possible.
The engineers identified epilepsy surgery as an ideal high-impact application through discussions with Joseph Neimat associate professor of neurological surgery.
and identify the location where the epileptic fits originate. But the straight needles they use can t reach the source region
Many groups have begun to apply CLARITY to probe brains donated from people who had diseases like epilepsy or autism
These visualization tools are prototypes of probes that could some day help researchers better understand the ion channel dysfunctions that lead to epilepsy cardiac arrhythmias
For example the Kv2. 1 channel that this probe binds to leads to epilepsy when it s not functioning properly. n addition the ability to better observe electrical signaling could help researchers map the brain at its most basic levels. nderstanding the molecular
A demonstrated neural firing-rate set point opens up a whole new approach to thinking about neurological disorders such as epilepsy in
to have an implant with electrodes paired with drug delivery pumps that could sense an oncoming epileptic seizure
This noninvasive approach could pave the way to using optogenetics in human patients to treat epilepsy and other neurological disorders,
This type of noninvasive approach to optogenetics could also represent a step toward developing optogenetic treatments for diseases such as epilepsy,
Pinning down the details of how individual neural circuits operate in epilepsy and other neurological disorders requires real-time observation of their locations firing patterns
#To make it happen the team removed parts of skull from three patients experiencing frequent drug-resistant epileptic seizures then attached a packet of electrodes to their exposed brains.
In animal studies this enabled reseachers to recognize the subtle brain signals that seem to give rise to seizures#a capability#he hopes doctors can use to better understand epilepsy in humans.
What more, Aprecia have just been awarded FDA approval for the first of 3d printed drug of its kind, the epilepsy drug Spritam.
myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy, they write.
This is good news for the large number of patients suffering from epilepsy-related afflictions, of which there are an estimated three million in the US alone
Surely epilepsy drugs already exist? Well you would be absolutely right, but the company argues that many patients have reported finding it difficult swallowing the large pills necessary. n my experience,
they mysteriously say about the exact way the technology works. y combining 3dp technology with a highly-prescribed epilepsy treatment,
was developed by Aprecia Pharmaceuticals to control seizures brought on by epilepsy. The company said that it planned to develop other medications using its 3d platform.
and is used to diagnose epilepsy and sleep disorders. Kokoon's app gives detailed feedback based on the nightly EEG readings to help you improve your quality of kip, according to Antos.
#FDA approves first 3d printed drug Aprecia Pharmaceuticals owns Spritam (levetiracetam), a solid oral pill to treat epileptic seizures.
Levetiracetam is prescribed already widely for epilepsy. Aprecia said the new delivery formulation is designed to help patients who struggle with current dosage forms,
The specific FDA approval is for SPRITAM (levetiracetam) that used as a therapy for epileptics to help control partial onset seizures, myoclonic seizures,
which is seen also in epilepsy, a disorder increasingly found to be associated with ASD. Cells from individuals who have depressed autism exhibit levels of calcium signaling
says Stéfan Catheline, Inserm Research director and main author of this work. lzheimer disease, epilepsy, multiple sclerosis and hydrocephalus involve changes in the stiffness of the brain tissues.
and children who suffer from certain types of seizures caused by epilepsy. The tablet is manufactured through a layered process via 3d printing
and is designed to treat seizures in people suffering from epilepsy. It's a new version of a seizure medication that's been on the market for years."
an existing anticonvulsant used to treat epilepsy that has been available as a generic in the U s. since 2008.
was approved for oral use as a prescription adjunctive therapy in the treatment of epilepsy, the company said on Monday.
#Epilepsy Switch Discovered Approximately five percent of people suffers an epileptic attack, during which the nerve cells get out of their usual rhythm and fire in a very rapid frequency, over the course of their lives.
Scientists at the University of Bonn and the Hebrew University of Jerusalem (Israel) have decoded a central signal cascade associated with epileptic seizures.
If the researchers blocked a central switch in epileptic mice, the frequency and severity of the seizures decreased.
it was possible to observe the processes prior to the occurrence of epileptic seizures in living animals."
"It has also been known for a long time that following transient severe brain injury and prior to an initial spontaneous epileptic seizure, the concentration of free zinc ions increases in the hippocampus.
This leads to a large increase in the amount of a special calcium ion channel in the nerve cells and overall, this significantly boosts the risk of epileptic seizures.
The scientists demonstrated the fact that the transcription factor MTF1 plays a central role in this connection using an experiment on mice suffering from epilepsy."
we inhibited MTF1 in the epileptic mice and as a result, the seizures in the animals were much rarer
This makes it possible to examine the processes which take place during the development of epilepsy in a living animal."
"If the fluorescence molecules glow, this indicates that the mouse is developing chronic epileptic seizures, "says the molecular biologist Prof.
Epilepsy is a typical example of a condition for which many drugs could not be commercialised because of their harmful effects,
During an epileptic seizure, the nerve cells in a specific area of the brain are activated suddenly in an excessive manner.
the researchers reproduced the hyperexcitability of epileptic neurons in mouse brains in vitro. They then injected GABA,
it may be possible to use this technology to treat patients with epilepsy who are resistant to conventional treatments,
In addition to epilepsy, this state-of-the-art technology, combined with existing drugs, offers new opportunities for many brain diseases that remain difficult to treat at this time e
"Alzheimer's disease, epilepsy, multiple sclerosis and hydrocephalus involve changes in the stiffness of the brain tissues. This new technique allows their detection,
both groups are studying people with epilepsy who already have implanted electrodes. The researchers can use these electrodes both to record brain activity
researchers asked 12 people with epilepsy to look at pictures and then recall up to 90 seconds later which ones they had seen.
) USC biomedical engineer Dong Song, a member of the team, says that the group has tried the stimulation on a woman with epilepsy,
again by working with people with epilepsy, that stimulating a region called the medial temporal lobe, which houses the hippocampus, improves memory that is functioning poorly.
Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain.
enables localised inhibition of epileptic seizure in brain tissue in vitro. This research is published in the journal Advanced Materials.
Epilepsy is a typical example of a condition for which many drugs could not be commercialised because of their harmful effects,
when they might have been effective for treating patients resistant to conventional treatments 1. During an epileptic seizure,
the researchers reproduced the hyperexcitability of epileptic neurons in mouse brains in vitro. They then injected GABA,
In addition to epilepsy this state-of-the-art technology, combined with existing drugs, offers new opportunities for many brain diseases that remain difficult to treat at this time a
the optoclamp could facilitate research into new therapies for epilepsy, Parkinson disease, chronic pain and even depression. ur work establishes a versatile test bed for creating the responsive neurotherapeutic tools of the future,
Potential applications include chronic pain, epilepsy, tinnitus, phantom limb syndrome and other nervous systems disorders where the brain has overreacted to the loss of normal inputs.
and could have implications that go far beyond basic neuroscience from informing education policy to developing new therapies for neurological disorders such as epilepsy.
when we age, has enormous implications that go beyond fundamental neuroscience, from informing education policies to developing new therapies for neurological disorders such as epilepsy
which is seen also in epilepsy, a disorder increasingly found to be associated with ASD. Cells from individuals who have depressed autism exhibit levels of calcium signaling
says Stéfan Catheline, Inserm Research director and main author of this work. lzheimer disease, epilepsy, multiple sclerosis and hydrocephalus involve changes in the stiffness of the brain tissues.
#Researchers discover an epilepsy switch A team from the University of Bonn uses a new approach to solve an old mystery Scientists at the University of Bonn
and the Hebrew University of Jerusalem (Israel) have decoded a central signal cascade associated with epileptic seizures.
If the researchers blocked a central switch in epileptic mice, the frequency and severity of the seizures decreased.
it was possible to observe the processes prior to the occurrence of epileptic seizures in living animals.
or her life suffers an epileptic attack, during which the nerve cells get out of their usual rhythm and fire in a very rapid frequency.
these channels act like a doorman to regulate the entry of calcium ions in the nerve cells. t has also been known for a long time that following transient severe brain injury and prior to an initial spontaneous epileptic seizure, the concentration of free zinc ions
This leads to a large increase in the amount of a special calcium ion channel in the nerve cells and overall, this significantly boosts the risk of epileptic seizures.
The scientists demonstrated the fact that the transcription factor MTF1 plays a central role in this connection using an experiment on mice suffering from epilepsy. sing a genetic method,
we inhibited MTF1 in the epileptic mice and as a result, the seizures in the animals were much rarer
This makes it possible to examine the processes which take place during the development of epilepsy in a living animal. f the fluorescence molecules glow,
this indicates that the mouse is developing chronic epileptic seizures, says the molecular biologist Prof. Dr. Susanne Schoch from the department of Neuropathology at the University of Bonn.
Hope for new options for diagnosis and treatment The scientists hope that new treatment options will open up for epilepsy patients
Spritam is an epilepsy medication used to treat seizures in children and adults. It's porous thanks to the 3d printing process,
noted Spritam is designed to help epilepsy patients adhere to their treatment regimen and should help children and seniors in particular.
#Epilepsy drug is approved first FDA 3d printed pill The first 3d printed pill has been approved for use by the US Food and Drug Administration (FDA.
Spritam (levetiracetam) is an oral adjunctive therapy to treat a range of seizures in adults and children with epilepsy.
000mg that disintegrate in the patient in less than 10 seconds. y combining 3d printing technology with a highly-prescribed epilepsy treatment,
including the disambiguation of electroencephalograph patterns from epileptic seizure patients; detection of anomalous cardiac activity from heart recordings;
It is used to watch for epileptic seizures and then stop them with electrical pulses. Altogether, U s. doctors bill for about $2. 6 billion worth of neural stimulation devices a year, according to industry estimates.
Plachta says the procedure for implanting the device in humans would be similar to one used in an existing technique that uses vagal-nerve stimulation to treat epilepsy.
--whose deregulation is associated with diseases ranging from diabetes to cancer to epilepsy--have gradually been brought to light.
may one day be used to treat pain, depression, epilepsy, and other neurological disorders in people by targeting therapies to specific brain circuits.
The scientists say the technology could be used to one day treat pain, epilepsy, depression and other neurological disorders.
The brain activity was recorded in the USA from 7 epileptic patients who participated voluntarily in the study during their clinical treatments.
But the potential for applying these surface implants is huge--for example in epilepsy, Parkinson's disease and pain management.
and neurodegenerative disorders, including depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's disease, AIDS dementia complex, asphyxia in newborns and epilepsy.
epilepsy or intellectual disability (see this review article for further background). But they also can be completely benign
#Novel compound switches off epilepsy development In temporal lobe epilepsy seizures arise in the hippocampus and other structures of the limbic system located in the temporal lobe when a cascade of molecular and cellular events results in aberrant brain wiring.
Temporal lobe epilepsy (TLE) or limbic epilepsy is a common adult epileptic disorder characterized by spontaneous recurrent seizures that may also spread to other brain regions triggering secondary severe generalized seizures.
Epilepsy is a chronic neurological disorder characterized by recurrent seizures. It's estimated that 66 million people in the world have epilepsy.
In the US 1 in 26 people will develop epilepsy at some time during their lifetime.
The incidence of epilepsy is higher in young children and older adults. Although the cause of epilepsy is unknown there are some types of epilepsy associated with previous brain injury.
Recurrent seizures might cause brain damage. According to the Epilepsy Foundation temporal lobe epilepsy is the most common form of partial or localization related epilepsy.
It accounts for approximately 60%of all patients with epilepsy. The medial form accounts for almost 80%of all temporal lobe seizures.
While medial temporal lobe epilepsy is a very common form of epilepsy it is also frequently resistant to medications.
The overall prognosis for patients with drug-resistant medial temporal lobe epilepsy includes a higher risk for memory and mood difficulties.
This in turn leads to impairments in quality of life and an increased risk for death as observed in patients who have frequent seizures failing to respond to treatment.
These observations will contribute to our ability to predict epileptic events define key modulators of brain circuits especially after a brain injury
and provide potential biomarkers and therapeutic approaches for epileptogenesis says Dr. Musto o
#Researchers use sound to slow down speed up and block light Researchers from the University of Illinois at Urbana-Champaign have demonstrated experimentally for the first time the phenomenon of Brillouin Scattering Induced Transparency (BSIT)
and to understanding the basis of neurodevelopmental and neurodegenerative disorders such as schizophrenia Alzheimer's disease and epilepsy.
Professor Mahiran said in pharmaceuticals an innovation has produced successfully a drugs delivery method to penetrate the'blood brain barrier'especially for diseases that are associated with the brain such as Alzheimer Parkinson epilepsy and meningitis.
and epilepsy to abnormal liver function and the inability to make tears. The leader of the research effort Tadashi Suzuki notes that
and severe epilepsy and died aged six in 2009. Critics say the technique will lead to the creation of genetically modified"designer babies"however,
This approach is also being studied as a treatment for other disorders, such as epilepsy. Today technology is limited, not by the electronics,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011